Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study Data
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study Data
Authors
Keywords
-
Journal
MOLECULES
Volume 27, Issue 12, Pages 3680
Publisher
MDPI AG
Online
2022-06-13
DOI
10.3390/molecules27123680
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Advances in the pathogenesis of psoriasis: from keratinocyte perspective
- (2022) Xue Zhou et al. Cell Death & Disease
- Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial
- (2021) Salomon M. Stemmer et al. Cancers
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Therapeutic pipeline in nonalcoholic steatohepatitis
- (2021) Raj Vuppalanchi et al. Nature Reviews Gastroenterology & Hepatology
- Randomised clinical trial: A phase 2 double‐blind study of namodenoson in non‐alcoholic fatty liver disease and steatohepatitis
- (2021) Rifaat Safadi et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Cancer biology and molecular genetics of A3 adenosine receptor
- (2021) Chiara Mazziotta et al. ONCOGENE
- Management of Rheumatoid Arthritis: An Overview
- (2021) Andrei-Flavius Radu et al. Cells
- Navigating the new landscape of second‐line treatment in advanced hepatocellular carcinoma
- (2020) Lorenza Rimassa et al. LIVER INTERNATIONAL
- Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy
- (2019) Shira Cohen et al. Drug Design Development and Therapy
- Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A3 Adenosine Receptor Agonist Piclidenoson
- (2018) Shira Cohen et al. Journal of Immunology Research
- A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy
- (2017) Kenneth A. Jacobson et al. MEDICINAL RESEARCH REVIEWS
- The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis
- (2016) Pnina Fishman et al. CLINICAL RHEUMATOLOGY
- Adenosine arrests breast cancer cell motility by A3 receptor stimulation
- (2016) Carola Ledderose et al. Purinergic Signalling
- Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
- (2015) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- An adenosine A3 receptor agonist inhibits DSS-induced colitis in mice through modulation of the NF-κB signaling pathway
- (2015) Tianhua Ren et al. Scientific Reports
- A3Adenosine Receptor Allosteric Modulator Induces an Anti-Inflammatory Effect:In VivoStudies and Molecular Mechanism of Action
- (2014) Shira Cohen et al. MEDIATORS OF INFLAMMATION
- The ACR20 and defining a threshold for response in rheumatic diseases: too much of a good thing
- (2014) David T Felson et al. ARTHRITIS RESEARCH & THERAPY
- CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation Study
- (2013) S. M. Stemmer et al. ONCOLOGIST
- Pharmacological and therapeutic effects of A3 adenosine receptor agonists
- (2011) Pnina Fishman et al. DRUG DISCOVERY TODAY
- Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial
- (2011) M. David et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver
- (2010) S. Cohen et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment
- (2009) S. Bar-Yehuda et al. ARTHRITIS AND RHEUMATISM
- The anti-inflammatory target A3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn’s disease
- (2009) A. Ochaion et al. CELLULAR IMMUNOLOGY
- The A 3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-κB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats
- (2008) A. Ochaion et al. BIOCHEMICAL PHARMACOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started